Immune checkpoint inhibitors use in liver transplantation for hepatocellular carcinoma: a global cohort study.

ABSTRACT:

Background

Hepatocellular carcinoma (HCC) remains a major contributor to global cancer mortality, with liver transplantation (LT) offering curative potential for patients in the early stages. While immune checkpoint inhibitors (ICIs) are effective in managing tumor progression, concerns about graft rejection persist. This study investigates how peri-LT ICIs administration affects rejection rates and survival outcomes in HCC patients.

Methods

This global study analyzed 386 HCC patients receiving Peri-LT ICIs therapy, integrating data from a systematic literature review and institutional registries. The risk of graft rejection and survival outcomes were assessed using logistic and Cox regression, along with restricted cubic splines modeling dose-response dynamics.

Results</

SUBMITTER: Ma D 

PROVIDER: S-EPMC12403418 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature